126 related articles for article (PubMed ID: 11503811)
1. Raloxifene: new preparation. Not better than oestrogen.
Prescrire Int; 1999 Dec; 8(44):165-7. PubMed ID: 11503811
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene. Not better than estrogen.
Can Fam Physician; 2000 Aug; 46():1592-6, 1599-603. PubMed ID: 10955178
[TBL] [Abstract][Full Text] [Related]
3. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
4. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
5. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
7. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
Prescrire Int; 2000 Dec; 9(50):190-1. PubMed ID: 11475503
[TBL] [Abstract][Full Text] [Related]
9. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
10. Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
Prescrire Int; 2000 Jun; 9(47):70-2. PubMed ID: 11010741
[TBL] [Abstract][Full Text] [Related]
11. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
12. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
Legrand E; Hoppé E; Chappard D; Audran M
Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
[TBL] [Abstract][Full Text] [Related]
13. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
14. [Raloxifene in postmenopausal women].
Trémollières F; Ribot C
Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
[TBL] [Abstract][Full Text] [Related]
15. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
Qu Y; Wong M; Thiebaud D; Stock JL
Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
[TBL] [Abstract][Full Text] [Related]
16. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
Burckhardt P
Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
18. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
Higuchi T; Mizunuma H
Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene therapy in the reduction of fractures.
Cefalu CA
Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
[No Abstract] [Full Text] [Related]
20. Raloxifene reduces fractures in postmenopausal women with osteoporosis.
Reginster JY; Devogelaer JP
Clin Orthop Relat Res; 2006 Feb; 443():48-54. PubMed ID: 16462425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]